Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid–liquid extraction

Synthesis of 2H‐ and 13C‐labelled sunitinib and its primary metabolite

“…monkey blood samples, have been published. 9 Unfortunately, the internal standard and its synthesis used in this study was not completely specified by the authors. One might conclude from the details provided (m/z = 409, most probably ESI 1 ), that a sunitinib-d 10 analogue was used.…”

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma

“…So far, analytical methods developed for pharmacokinetic investigations of sunitinib were based on liquid chromatography-mass spectrometry methods (LC-MS or LC-MS-MS), and required costly MS equipment, most often available in centralized laboratory structures [6,[9][10][11]. The advantage of LC-MS method is its high sensitivity, around 0.1 ng/ml for sunitinib and SU12662.…”

“…So far, published techniques of sunitinib analysis are based on high-performance liquid chromatography-tandem mass spectrometric (LC/MS-MS) methods [6,[9][10][11]. Routine feasibility of sunitinib analysis is thus limited by the need for the laboratory to dispose of such a specific equipment.…”

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

“…This interaction resulted in a decreased systemic exposure to sunitinib and an increased exposure to its active metabolite, SU12662. Although the exact contribution of the active metabolite SU12662 to the toxicity and efficacy pattern of sunitinib in humans is unknown, preclinical data point towards equipotent inhibitory capacities (Baratte et al, 2004). Ifosfamide is a potent inhibitor of CYP3A, the enzyme mainly responsible for conversion of sunitinib into SU12662 (Faivre et al, 2006).…”